12 Analysts Assess 10x Genomics: What You Need To Know
Portfolio Pulse from Benzinga Insights
In the past three months, 12 analysts have provided ratings for 10x Genomics (NASDAQ:TXG), ranging from bullish to bearish. The average 12-month price target has decreased by 33.02% to $33.0. Analysts have recently lowered their ratings and price targets, reflecting a cautious outlook on the company's performance.
July 16, 2024 | 2:02 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
12 analysts have provided ratings for 10x Genomics (NASDAQ:TXG) over the past three months, with a notable decrease in the average 12-month price target by 33.02% to $33.0. Recent ratings show a cautious outlook on the company's performance.
The significant reduction in the average 12-month price target by 33.02% and the lowering of ratings by multiple analysts indicate a bearish sentiment towards 10x Genomics. This is likely to negatively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100